Axel Hauschild, MD
Novel systemic therapies in the neoadjuvant and adjuvant settings have shown promising outcomes for locally advanced melanoma and may reduce the proportion of patients who need complete lymphadenectomy. Optimizing systemic therapy to maximize efficiency and minimize adverse events (AEs) will be the next step moving forward, according to panelists who participated in an OncLive
The trend in melanoma therapy has been toward combinations, and Hauschild said he expects that to continue. Sequencing drugs correctly will be important, he noted.
Role of Surgery in Locoregional Disease
... to read the full story